| Literature DB >> 35024102 |
Peng Chen1, Bin Zhou2, Tao Wang2, Xiao Hu2, Yongqiang Ye1, Weidong Guo2.
Abstract
BACKGROUND: Laparoscopic distal pancreatectomy (LDP) has become a routine procedure in pancreatic surgery. Although robotic distal pancreatectomy (RDP) has not been popularized yet, it has shown new advantages in some aspects, and exploring its learning curve is of great significance for guiding clinical practice.Entities:
Mesh:
Year: 2022 PMID: 35024102 PMCID: PMC8747902 DOI: 10.1155/2022/7302222
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Figure 1Flow chart showing patient enrolment and surgical treatment strategies.
Figure 2Port placement for RDP (a) and LDP (b). C, camera port; R1–R3, robot arm ports; A1, assistant ports.
Baseline characteristics, pathology data, and outcomes of patients (MIPD).
| LDP ( | RDP ( |
| |
|---|---|---|---|
| Age, years, (mean ± SD) | 51.74 ± 15.90 | 50.06 ± 14.77 | 0.525 |
| Sex, | |||
| Male | 29 (30.5) | 16 (29.6) | |
| Female | 66 (69.5) | 38 (70.4) | 0.909 |
| BMI, kg/m2, (mean ± SD) | 24.23 ± 4.60 | 24.23 ± 3.59 | 0.995 |
| CA199, u/ml, median (IQR) | 11.0 (7.4–24.5) | 12.1 (8.3–17.2) | 0.941 |
| CEA, ng/ml, median (IQR) | 1.4 (1.0–2.3) | 1.4 (0.7–2.3) | 0.430 |
| CA125, u/ml, median (IQR) | 12.6 (8.2–17.2) | 13.6 (11.3–19.6) | 0.118 |
| Albumin, g/l, median (IQR) | 41.9 (40.0–44.9) | 42.2 (40.8–44.4) | 0.605 |
| HB, g/l, median (IQR) | 132.0 (125.5–146.0) | 129.5 (120.0–137.0) | 0.119 |
| PDD, | 2 (2.1) | 4 (7.4) | 0.190 |
| Comorbidities, | |||
| Hypertension | 22 (23.2) | 11 (20.4) | 0.694 |
| Diabetes | 15 (15.8) | 4 (7.4) | 0.140 |
| ASA, | |||
| ASA 1 | 15 (15.8) | 7 (13.0) | |
| ASA 2 | 52 (54.7) | 39 (72.2) | |
| ASA 3 | 28 (29.5) | 8 (14.8) | 0.083 |
| ITD, mm, (mean ± SD) | 43.83 ± 23.33 | 38.30 ± 20.56 | 0.149 |
| Pathologic diagnosis, | |||
| PDAC | 12 (12.6) | 8 (14.8) | |
| SCN | 27 (28.4) | 16 (29.6) | |
| MCN | 12 (12.6) | 8 (14.8) | |
| SPN | 25 (26.3) | 11 (20.4) | |
| PNT | 12 (12.6) | 7 (13.0) | |
| Others | 7 (7.4) | 4 (7.4) | 0.979 |
| Specimen size, mm, (mean ± SD) | 46.04 ± 28.15 | 38.81 ± 21.20 | 0.103 |
|
| 94 (98.9) | 54 (100.0) | 1.000 |
| Lymphatic metastasis, | 4 (4.2) | 2 (3.7) | 1.000 |
| Operative time, min, median (IQR) | 210 (180–270) | 240 (200–270) | 0.138 |
| Blood loss, ml, median (IQR) | 100 (50–200) | 100 (50–200) | 0.400 |
| FFT, days, median (IQR) | 3 (3–3) | 2.5 (2–3) | 0.001 |
| Diet start time, days, median (IQR) | 3 (3–4) | 3 (2–4) | 0.002 |
| Hospital stay, days, median (IQR) | 14 (11–17) | 13 (11–15) | 0.051 |
| PHS, days, median (IQR) | 8 (7–11) | 8 (5–9) | 0.026 |
| Reoperation, | 2 (2.1) | 2 (3.7) | 0.621 |
| Complication, | |||
| Pulmonary infection | 4 (4.2) | 0 | 0.297 |
| Abdominal infection | 8 (8.4) | 0 | 0.070 |
| Wound infection | 2 (2.1) | 1 (1.9) | 1.000 |
| Pancreatic fistula | 52 (54.7) | 32 (59.3) | 0.593 |
| B + C fistula | 24 (25.3) | 15 (27.1) | 0.737 |
| Bleeding | 5 (5.3) | 2 (3.7) | 1.000 |
| Mortality | 0 | 0 | |
| CD grade 3/4, | 8 (8.4) | 3 (5.6) | 0.751 |
| Operation cost, USD, (mean ± SD) | 3237.7 ± 1442.1 | 6998.4 ± 1314.9 | <0.001 |
| Total cost, USD, (mean ± SD) | 8256.8 ± 2149.0 | 11522.7 ± 1569.3 | <0.001 |
MIPD, minimally invasive distal pancreatectomy; RDP, robot-assisted distal pancreatectomy; LDP, laparoscopic distal pancreatectomy; BMI, body mass index; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; HB, hemoglobin; PDD, pancreatic duct dilatation; ASA, American Society of Anesthesiology; ITD, imaging tumor diameter; PDAC, pancreatic ductal adenocarcinoma; SCN, serous cystic neoplasms; MCN, mucinous cystic neoplasms; SPN, solid pseudopapillary neoplasms; PNT, pancreatic neuroendocrine tumor; FFT, first flatus time; PHS, postoperative hospital stay; CD, Clavien–Dindo; USD, U.S. dollar.
The preservation rate of spleen (benign and borderline neoplasms in MIPD).
| LDP ( | RDP ( |
| |
|---|---|---|---|
| Spleen preservation, | 42 (50.6) | 36 (78.3) | 0.002 |
| Operation methods, | |||
| Kimura's technique | 22 (26.5) | 23 (50.0) | 0.007 |
| Warshaw's technique | 20 (24.1) | 13 (28.3) | 0.604 |
MIPD, minimally invasive distal pancreatectomy; RDP, robot-assisted distal pancreatectomy; LDP, laparoscopic distal pancreatectomy.
The follow-up data (MIPD).
| LDP ( | RDP ( |
| |
|---|---|---|---|
| Endocrine dysfunction, | 15 (17.4) | 9 (17.6) | 0.976 |
| Exocrine dysfunction, | 2 (2.3) | 0 | 0.529 |
| Thrombocytosis | 18 | 3 | |
| OPSI | 1 | 0 | |
| Splenic infarction | 0 | 0 | |
| Mortality | 6 | 1 |
MIPD, minimally invasive distal pancreatectomy; RDP, robot-assisted distal pancreatectomy; LDP, laparoscopic distal pancreatectomy; OPSI, overwhelming postsplenectomy infection.
Figure 3The CUSUM curve according to the operation time. The decreasing point for the operation time begins at the 32nd operation.
Baseline characteristics, pathology data, and outcomes of patients (the first 32 versus the last 22 RDPs).
| Early experience ( | Late experience ( |
| |
|---|---|---|---|
| Age, years, (mean ± SD) | 50.72 ± 15.52 | 49.09 ± 13.91 | 0.695 |
| Sex, | |||
| Male | 9 (28.1) | 7 (31.8) | |
| Female | 23 (71.9) | 15 (68.2) | 0.770 |
| BMI, kg/m2, (mean ± SD) | 24.31 ± 3.95 | 24.11 ± 3.08 | 0.845 |
| CA199, u/ml, median (IQR) | 13.9 (9.6–21.4) | 10.9 (7.6–16.2) | 0.311 |
| CEA, ng/ml, median (IQR) | 1.6 (1.0–2.3) | 1.0 (0.5–2.5) | 0.134 |
| CA125, u/ml, median (IQR) | 16.4 (12.0–22.7) | 13.2 (10.3–18.2) | 0.111 |
| Albumin, g/l, median (IQR) | 42.0 (40.9–44.0) | 42.5 (40.4–45.8) | 0.449 |
| HB, g/l b, (mean ± SD) | 128.31 ± 20.00 | 132.36 ± 17.48 | 0.445 |
| PDD, | 3 (9.4) | 1 (4.5) | 0.638 |
| Comorbidities, | |||
| Hypertension | 7 (21.9) | 4 (18.2) | 0.741 |
| Diabetes | 2 (6.3) | 2 (9.1) | 1.000 |
| ASA, | |||
| ASA 1 | 5 (15.6) | 2 (9.1) | |
| ASA 2 | 23 (71.9) | 16 (72.7) | |
| ASA 3 | 4 (12.5) | 4 (18.2) | 0.750 |
| ITD, mm, (mean ± SD) | 37.06 ± 23.71 | 40.09 ± 15.19 | 0.600 |
| Pathologic diagnosis, | |||
| PDAC | 4 (12.5) | 4 (18.2) | |
| SCN | 10 (31.3) | 6 (27.3) | |
| MCN | 6 (18.8) | 2 (9.1) | |
| SPN | 4 (12.5) | 7 (31.8) | |
| PNT | 5 (15.6) | 2 (9.1) | |
| Other | 3 (9.4) | 1 (4.5) | 0.548 |
| Specimen size, mm, (mean ± SD) | 38.25 ± 24.33 | 39.64 ± 16.11 | 0.816 |
|
| 0 | 0 | |
| Lymphatic metastasis, | 0 | 2 (9.1) | 0.161 |
| Operative time, min, median (IQR) | 240 (210–300) | 200 (180–260) | 0.011 |
| Blood loss, ml, median (IQR) | 100 (50–300) | 90 (50–100) | 0.052 |
| FFT, days, median (IQR) | 3 (2–3) | 2 (2–3) | 0.004 |
| Diet start time, days, median (IQR) | 3 (2–4) | 3 (2–3) | 0.027 |
| Hospital stay, days, median (IQR) | 13 (11–16) | 11 (10–14) | 0.047 |
| PHS, days, median (IQR) | 8 (5.5–9.5) | 7 (5–8) | 0.372 |
| Reoperation, | 2 (6.3) | 0 | 0.508 |
| Complication, | |||
| Pulmonary infection | 0 | 0 | |
| Abdominal infection | 0 | 0 | |
| Wound infection | 1 (3.1) | 0 | 1.000 |
| Pancreatic fistula | 18 (56.3) | 14 (63.6) | 0.587 |
| B + C fistula | 7 (21.9) | 8 (36.4) | 0.243 |
| Bleeding | 2 (6.3) | 0 | 0.508 |
| Mortality | 0 | 0 | |
| CD grade 3 + 4, | 3 (9.4) | 0 | 0.262 |
RDP, robot-assisted distal pancreatectomy; BMI, body mass index; CA199, carbohydrate antigen 199; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; HB, hemoglobin; PDD, pancreatic duct dilatation; ASA, American Society of Anesthesiology; ITD, imaging tumor diameter; SCN, serous cystic neoplasms; MCN, mucinous cystic neoplasms; SPN, solid pseudopapillary neoplasms; PNT, pancreatic neuroendocrine tumor; FFT, first flatus time; PHS, postoperative hospital stay; CD, Clavien–Dindo
The preservation rate of spleen (the first 32 versus the last 22 RDPs) (benign and borderline neoplasms).
| Early experience ( | Late experience ( |
| |
|---|---|---|---|
| Spleen preservation, | 22 (78.6) | 14 (77.8) | 0.949 |
| Operation methods, | |||
| Kimura's technique | 15 (53.6) | 8 (44.4) | 0.546 |
| Warshaw's technique | 7 (25.0) | 6 (33.3) | 0.540 |
RDP, robot-assisted distal pancreatectomy.